{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endothelial+Cells",
    "query": {
      "condition": "Endothelial Cells"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 181,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endothelial+Cells&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T04:41:53.731Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07070232",
      "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "BNT326",
          "type": "DRUG"
        },
        {
          "name": "Pumitamig",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Paroxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1438,
      "start_date": "2025-08-12",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-07-24T04:41:53.731Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07070232"
    },
    {
      "nct_id": "NCT02406521",
      "title": "Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "Radium-223",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2015-04",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-03-04",
      "last_synced_at": "2026-07-24T04:41:53.731Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02406521"
    },
    {
      "nct_id": "NCT01972113",
      "title": "Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Insulin Resistance",
        "Insulin Sensitivity",
        "Prediabetes",
        "Dyslipidemia",
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Placebo-Control",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Augusta University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 30,
      "start_date": "2013-09",
      "completion_date": "2020-12-30",
      "has_results": false,
      "last_update_posted_date": "2019-11-19",
      "last_synced_at": "2026-07-24T04:41:53.731Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01972113"
    },
    {
      "nct_id": "NCT01729975",
      "title": "Comparative Study of Specular Microscope for Cell Density, Coefficient of Variation, Hexagonality and Corneal Thickness",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Corneal and Endothelial Cell Measurements"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Nidek Co. LTD.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 80,
      "start_date": "2012-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-11-21",
      "last_synced_at": "2026-07-24T04:41:53.731Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01729975"
    },
    {
      "nct_id": "NCT02429843",
      "title": "A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "TRC105",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2015-11-02",
      "completion_date": "2019-12",
      "has_results": false,
      "last_update_posted_date": "2021-06-28",
      "last_synced_at": "2026-07-24T04:41:53.731Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02429843"
    },
    {
      "nct_id": "NCT03782142",
      "title": "Effect on HIV Medications on EPC Cells",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "AIDS"
      ],
      "interventions": [
        {
          "name": "Tenofovir",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine",
          "type": "DRUG"
        },
        {
          "name": "Prezcobix",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sabyasachi Sen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "40 Years to 70 Years · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2018-11-01",
      "completion_date": "2021-12-14",
      "has_results": false,
      "last_update_posted_date": "2022-03-22",
      "last_synced_at": "2026-07-24T04:41:53.731Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03782142"
    },
    {
      "nct_id": "NCT03797326",
      "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Triple Negative Breast Cancer",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Colorectal Cancer",
        "Glioblastoma",
        "Biliary Tract Cancers",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 611,
      "start_date": "2019-02-12",
      "completion_date": "2024-10-28",
      "has_results": true,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-07-24T04:41:53.731Z",
      "location_count": 14,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03797326"
    },
    {
      "nct_id": "NCT01736462",
      "title": "Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Corneal Endothelial Cell Changes"
      ],
      "interventions": [
        {
          "name": "Mapracorat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2013-02",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2013-11-26",
      "last_synced_at": "2026-07-24T04:41:53.731Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01736462"
    },
    {
      "nct_id": "NCT00132704",
      "title": "An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Neoplasms",
        "Colorectal Neoplasms",
        "Melanoma",
        "Small Cell Lung Cancer",
        "Liposarcoma"
      ],
      "interventions": [
        {
          "name": "Ionizing radiation (IR) therapy",
          "type": "RADIATION"
        },
        {
          "name": "Ionizing radiation (IR)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 149,
      "start_date": "2004-08",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-07-24",
      "last_synced_at": "2026-07-24T04:41:53.731Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00132704"
    },
    {
      "nct_id": "NCT01250964",
      "title": "Endothelial Cell Loss and Induced Astigmatism After Wound-directed and Wound-assisted IOL Injection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cataracts",
        "Cataract Surgery"
      ],
      "interventions": [
        {
          "name": "Lens insertion during cataract surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2010-04",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2010-12-01",
      "last_synced_at": "2026-07-24T04:41:53.731Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01250964"
    }
  ]
}